Fulgent Genetics Q2 2026: Revenue Rises, GAAP Loss Persists, Cash Hoard Fuels Buybacks

Key numbers at a glance

• Revenue: $85.4 million, up 20.1% sequentially
• GAAP gross profit: $25.7 million; GAAP gross margin 30.1%
• Non-GAAP gross profit: $26.8 million; Non-GAAP gross margin 31.3%
• GAAP EPS (loss per share): $(1.05)
• Non-GAAP EPS (loss per share): $(0.58)
• Stock buybacks: ~1.5 million shares repurchased for $23.8 million in Q2 2026
• Cash position: $551.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of ~$106.1 million
• Revenue guidance: Full-year revenue forecast revised to $330.0–$340.0 million

What happened, and what it could portend

Fulgent’s quarter reads like a paradox the market accepts in biology: growth on the top line paired with GAAP losses that don’t quite evaporate on a cash basis. Revenue advanced to $85.4 million, a clean 20.1% sequential lift, suggesting demand for its genetics services remains intact as the company continues investing in growth engines. The GAAP gross profit of $25.7 million yields a 30.1% gross margin, while the Non-GAAP measure sits at $26.8 million with a 31.3% margin. Translation: the math says the underlying business is capable of producing margin, but accounting choices still cast a shadow over the reported profitability.

EPS is where the numbers bite back. GAAP loss of $29.5 million, or $1.05 per share, sits alongside a Non-GAAP loss of $16.2 million, or $0.58 per share. The divergence underlines the classic investor question: is the company approaching profitability on a cash-operating basis, or are we still watching non-cash adjustments that push the headline into negative territory? The company does not provide explicit EPS consensus data in the excerpt, so whether this prints as an earnings surprise remains a read-through for analysts who will compare GAAP EPS and Non-GAAP EPS to the Street’s consensus estimates.

Capital discipline shows up in the form of a buyback blitz. The firm repurchased roughly 1.5 million shares for $23.8 million in the quarter, signaling management’s confidence in the stock and an attempt to return capital while the business story evolves. The balance sheet underpins this stance: the quarter closed with $551.5 million in cash and equivalents, restricted cash, and marketable securities, though this figure excludes an anticipated tax refund of about $106.1 million—an unsigned note in the cushion under the mattress, so to speak. And the forecast follows suit: the company nudged its revenue outlook higher to $330.0-$340.0 million for the year, implying continued demand momentum and a belief that cost dynamics can keep pace with growth.

Outlook, implications, and what peers might watch

The Q2 print reinforces a familiar storyline in specialty genetics: robust top-line activity can coexist with GAAP losses, particularly when investments in pipeline, sales, and administration weigh on the bottom line. The modest improvement in gross margins—GAAP 30.1% vs Non-GAAP 31.3%—is encouraging, but the optics will depend on whether operating leverage materializes as volumes scale. For sector peers, the takeaway is twofold: disciplined capital allocation—evidenced by the buyback—can accompany a growth narrative if cash generation remains strong; and if revenue momentum softens, companies will be tugged toward clearer paths to GAAP profitability or at least more durable non-GAAP profitability signals. The market will scrutinize whether this is a momentary cadence or the prelude to a sustainable pivot.

In the broader landscape of genetic testing and diagnostic services, investors will watch for continued revenue growth, margin stabilization, and the durability of cash generation amid competitive pressures and regulatory dynamics. If FLGT can keep the topline climbing while narrowing the delta between GAAP and Non-GAAP profitability, it may begin to attract a wider audience of investors who prize cash returns and a clearer EBITDA story as much as a strong scientific pipeline.

Note Regarding Non-GAAP Financial Measures

The company notes that non-GAAP metrics—such as non-GAAP gross profit and margin, non-GAAP income (loss) and per-share figures, and adjusted EBITDA—are intended to supplement GAAP results and are reconciled to the most directly comparable GAAP measures in accompanying tables. The non-GAAP figures exclude items the company believes may not reflect ongoing performance, so readers should treat them as supplementary to GAAP results and not as standalone indicators of trajectory.

Bottom line

Fulgent’s Q2 2026 narrative centers on a growing revenue base and a substantial cash cushion that funds a meaningful buyback while the company’s GAAP losses linger. The outgrowth of this story hinges on whether current momentum translates into sustainable profitability on a cash-operating basis and whether the revenue forecast holds under the strain of ongoing investment in growth. For FLGT, the near-term calculus looks like this: preserve the balance sheet health, keep the revenue engine fired, and hope the EPS consensus shifts in lockstep with Non-GAAP improvements. If that happens, the stock’s buyback signal could be the punctuation mark on a story that, up to now, reads more like a work-in-progress than a finished thesis.